Next-Generation Proteomics of Brain Extracellular Vesicles in Schizophrenia Provide New Clues on the Altered Molecular Connectome
Cristina Lorca,
María Fernández-Rhodes,
Jose Antonio Sánchez Milán,
María Mulet,
Félix Elortza,
Alfredo Ramos-Miguel,
Luis F. Callado,
J. Javier Meana,
Maria Mur,
Iolanda Batalla,
Elisabet Vilella,
Aida Serra,
Xavier Gallart-Palau
Affiliations
Cristina Lorca
Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain
María Fernández-Rhodes
Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain
Jose Antonio Sánchez Milán
Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain
María Mulet
Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain
Félix Elortza
Proteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, Science and Technology Park of Bizkaia, 48160 Derio, Spain
Alfredo Ramos-Miguel
Department of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain
Luis F. Callado
Department of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain
J. Javier Meana
Department of Pharmacology, University of the Basque Country UPV/EHU, 48940 Leioa, Spain
Maria Mur
Psychiatry Department, Hospital Universitari Santa Maria, Medicine Department, Universitat de Lleida (UdL), 25198 Lleida, Spain
Iolanda Batalla
Psychiatry Department, Hospital Universitari Santa Maria, Medicine Department, Universitat de Lleida (UdL), 25198 Lleida, Spain
Elisabet Vilella
Centro de Investigación Biomédica en Red en Salud Mental CIBERSAM, Instituto de Salud Carlos III, 43206 Reus, Spain
Aida Serra
Department of Medical Basic Sciences, Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), +Pec Proteomics Research Group (+PPRG), University of Lleida (UdL), 25198 Lleida, Spain
Xavier Gallart-Palau
Biomedical Research Institute of Lleida Dr. Pifarré Foundation (IRBLLEIDA), Neuroscience Area, +Pec Proteomics Research Group (+PPRG), University Hospital Arnau de Vilanova (HUAV), 80 Av. Rovira Roure, 25198 Lleida, Spain
Extracellular vesicles (EVs) are tiny membranous structures that mediate intercellular communication. The role(s) of these vesicles have been widely investigated in the context of neurological diseases; however, their potential implications in the neuropathology subjacent to human psychiatric disorders remain mostly unknown. Here, by using next-generation discovery-driven proteomics, we investigate the potential role(s) of brain EVs (bEVs) in schizophrenia (SZ) by analyzing these vesicles from the three post-mortem anatomical brain regions: the prefrontal cortex (PFC), hippocampus (HC), and caudate (CAU). The results obtained indicate that bEVs from SZ-affected brains contain region-specific proteins that are associated with abnormal GABAergic and glutamatergic transmission. Similarly, these vesicles from the analyzed regions were implicated in synaptic decay, abnormal brain immunity, neuron structural imbalances, and impaired cell homeostasis. Our findings also provide evidence, for the first time, that networks of molecular exchange (involving the PFC, HC, and CAU) are potentially active and mediated by EVs in non-diseased brains. Additionally, these bEV-mediated networks seem to have become partially reversed and largely disrupted in the brains of subjects affected by SZ. Taken as a whole, these results open the door to the uncovering of new biological markers and therapeutic targets, based on the compositions of bEVs, for the benefit of patients affected by SZ and related psychotic disorders.